Xiwagi Lu, Zhong YY, Yu HY, Xu J, Xie JY, Wen DW, Zhao L, Wang KY, Wang JB
Background: To analyze the clinical characteristics of IgG4 related diseases (IgG4-RD), identify the most commonly used therapeutic drugs, and explore the potential tumor markers of IgG4-RD.
Methods: 92 patients with IgG4 related diseases hospitalized in the Affiliated Hospital of Qingdao University from January 1, 2017 to December 31, 2021 were selected as the research object through the Yidu cloud system. Their clinical data were summarized and analyzed to summarize the clinical characteristics of IgG4-RD.
Results: The age of diagnosis of IgG4 related diseases in this group was 31-84 years old, and the average age of diagnosis was (58.098 ± 11.344) years old, including 65 males (70.65%) and 27 females (29.35%). The most frequently involved organs and tissues were lymph nodes (37 cases, accounting for 40.2%), pancreas (33 cases, accounting for 35.9%), and salivary glands (31 cases, accounting for 33.7%). In this group, 28 cases (30.4%) were involved in single organ tissue, 32 cases (34.8%) were involved in double organ and multiple organs, respectively. 91 patients were treated with hormone for IgG4 related diseases, and 71 patients were treated with immunosuppressive agents, of which 45 cases were treated with cyclophosphamide (63.38%). In this group, the proportion of IgG4 level greater than 40 g /L in tumor patients (18.18%) was significantly higher than that in non-tumor patients (1.23%) (P<0.05).
Conclusion: The incidence of IgG4 related diseases is more common in middle-aged and elderly men, and the patients with lymph node, salivary gland and pancreas are more common. About 2/3 of the patients are double organ and multi organ patients. The most common rheumatic complications in patients with IgG4-RD are primary biliary cirrhosis, rheumatoid arthritis and Sjogren's syndrome. The most common tumor in patients with IgG4-RD is malignant tumor of digestive system. IgG4 levels greater than 40 g/l in patients with IgG4 related diseases may be a potential indicator for predicting IgG4-RD associated tumors.